R&D News | pharmaphorum

News

Sanofi hands back neurology gene therapy rights to Voyager

Sanofi’s Genzyme unit has handed back rights to two neurology gene therapies to US biotech Voyager Therapeutics, as part of a rethink of the companies’ joint research.

News

The diagnosis Hepatitis written on a clipboard

VBI craters as investors react to Hep B vaccine data

VBI Vaccines has trumpeted top-line data from a trial pitting its hepatitis B virus (HBV) vaccine candidate against GlaxoSmithKline’s Engerix-B – but investors weren’t convinced, and its sh

News

bluebird offers instalment payments for Zynteglo gene therap...

bluebird bio is pricing its thalassaemia gene therapy Zynteglo at €1.57 million ($1.8 million) in Europe, but with an outcomes-based payment scheme to try to persuade healthcare systems to

News

GSK makes CRISPR play, funding Doudna lab in California

GlaxoSmithKline has forged an alliance with two leading CRISPR researchers that will see the creation of a new genomics research lab at the University of California.

News

Lilly’s Taltz scrapes win against Humira in psoriatic arthri...

Eli Lilly’s Taltz has beaten AbbVie’s blockbuster Humira in a psoriatic arthritis study involving patients who hadn’t been treated before with a disease-modifying drug, but only just.

News

Sobi cuts staff and buys Novimmune drug in refocus

Sobi has narrowed its focus to haematology and immunology, shedding staff and R&D projects in other areas whilst taking full control of a drug it licenses from Novimmune.

Sanofi hands back neurology gene therapy rights to Voyager

VBI craters as investors react to Hep B vaccine data

bluebird offers instalment payments for Zynteglo gene therap...

GSK makes CRISPR play, funding Doudna lab in California

Lilly’s Taltz scrapes win against Humira in psoriatic arthri...

Sobi cuts staff and buys Novimmune drug in refocus

Antiviral development in the age of AI: From pre-IND to earl...

Securing your ROI: Turning post-acquisition integration into...

News

Editor's Picks